Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript

Rick Eiswirth: That’s a pretty lengthy trial. I mean that’s – it’s the target, the DRC has on the trial is about 600 patients. We’re hoping that they will start nrolment in the – late in the fourth quarter of this year but it’s probably a multiyear trial before you’d see any readout. It’s being run by the DRCR. So yes, it’s being run by the DRCR. So we don’t control the time line on that trial.

Operator: [Operator Instructions] This concludes our question-and-answer session. I’d like to return the call over to Mr. Rick Eiswirth for closing remarks.

Rick Eiswirth: Thank you. I want to thank everybody for participating on today’s call and for your interest in support of Alimera. We do look forward to sharing our ongoing progress when we report fourth quarter and full year 2023 results early next year. Thank you all very much, and have a great day.

Operator: Conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.